Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5065 - Tackling fratricide to manufacture clinical grade NKG2D-CAR T cells for cancer therapy

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Cancer Biology

Tumour Site

Presenters

Benjamin Demoulin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

Authors

B. Demoulin, B. Eytan, D. Gilham

Author affiliations

  • R&d, Celyad SA, 1435 - Mont Saint Guibert/BE
More

Resources

Abstract 5065

Background

T cells bearing a chimeric antigen receptor (CAR) T-cell consisting of the fusion of the NKG2D NK receptor with the intracellular domain of CD3zeta (CYAD-01) can recognize eight stress ligands expressed in a large variety of cancers. However, activated T cells undergo stress and transiently express NKG2D ligands (NKG2DL). Consequently, CYAD-01 T cells kill sister cells preventing the large-scale manufacturing of CYAD-01 for clinical application.

Methods

Inclusion of the PI-3K inhibitor LY294002 into the manufacturing process was the first strategy used as an initial effort focused upon blunting the activity of the CAR T cells. We subsequently developed a process that included a NKG2D blocking antibody during the expansion phase of cell culture.

Results

LY294002 was shown to reversibly reduce NKG2D expression at the cell surface. Consequently, this inhibitor partially controlled fratricide during manufacturing and enhanced viability post-thawing which enabled the initiation of the THINK (NCT03018405) clinical trial. As the trial moved through the dose-escalation phase towards the upper dose level (production of more than 1010 cells), there was an increase in the level of manufacturing failures. This was largely linked to the effect of LY294002 upon T cell proliferation and the challenge faced manufacturing CAR T cells from patients with advanced cancer. Therefore, we subsequently developed a process that included a NKG2D blocking antibody during the expansion phase of cell culture. This strategy enabled the expansion of CYAD-01 T cells to the levels required for the THINK clinical trial. After fine tuning the process, the CYAD-01 CAR T cells generated showed high comparability to the CYAD-01 CAR T cells produced in the first part of the trial. This process has been in place for the THINK trial since January 2018.

Conclusions

Together, these results indicate that when fratricide is an issue preventing clinical development, CAR T cells can be efficiently manufactured through PI-3K inhibition and antibody mediated receptor blockade.

Clinical trial identification

Legal entity responsible for the study

Celyad SA.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

B. Demoulin B. Eytan, D. Gilham: Employee of Celyad SA.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.